Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Clinical trial NCT05285891 · RECRUITING

Trial details

NCT number: NCT05285891
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Multiple Sclerosis

Start date: 2023-02-07
Primary completion: 2030-05-01
Enrollment: 123

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.